The North America liver disease treatment market accounted for $6,970 million in 2019, and is expected to reach $8,318 million by 2027, registering a CAGR of 5. 2% from 2020 to 2027.
Medical care given to a patient suffering from liver diseases is termed as liver disease treatment. Furthermore, the treatment includes use of various drugs for different types of liver conditions. For instance, hepatitis B is a liver disease caused by a virus called hepatitis B virus (HBV). This condition is treated using antiviral drugs and can also be prevented by use of vaccines. Furthermore, other drugs that are used in treatment of hepatitis include immunoglobulin. Similarly, liver cancer is treated by using chemotherapy drugs and targeted therapy. In addition, some autoimmune liver related disorders are treated with the use of corticosteroids.
Furthermore, liver associated conditions also require liver transplant in many cases, where immunosuppressant drugs are used to prevent organ rejection. Thus, there are various types of liver treatments offered in the market such as anti-viral drugs, immunosuppressant drugs, vaccines, immunoglobulin, corticosteroid, targeted therapy, and chemotherapy drugs. In addition, these products are used to cure a range of liver diseases, which include hepatitis, autoimmune diseases, non-alcoholic fatty liver, and genetic disorders.
The major factors that contribute toward growth of the North America liver disease treatment market include increase in alcohol consumption & use of illegal drugs and The rise in prevalence of liver disease. Furthermore, it is also a primary cause for worsening of various liver conditions, which require treatment. For instance, consumption of large quantity of alcohol can lead to liver condition called alcoholic hepatitis, which, in turn, leads to liver inflammation that requires treatment. Furthermore, factors such as surge in geriatric population and increase in government and non-government awareness programs also boost growth of the North America liver disease treatment market. For instance, older patients who acquire hepatitis C infection are more likely to develop cirrhosis in the coming years, owing to accelerated fibrosis rate and decreased immunity.
However, stringent approval process related to drugs and resistance to antiviral drugs used in treatment of hepatitis B and hepatitis C of drugs restrict growth of the North America liver disease treatment market. For instance, approval processes require a huge capital investment. Moreover, any new drug manufacturing company that tries to enter into the market is bound to abide by these regulations. Therefore, these procedures are time consuming, which extends the time for their approval and commercialization and restricts growth of the market. Conversely, presence of strong pipeline products offer a lucrative opportunity for the market growth.
The North America liver disease treatment market is segmented on the basis of treatment type, disease type, and country to provide a detailed assessment of the market. By treatment type, the market is divided into antiviral drugs, immunosuppressants, vaccines, immunoglobulins, corticosteroids, targeted therapy, and chemotherapy. By disease type, it is divided into hepatitis, autoimmune diseases, non-alcoholic fatty liver disease (NAFLD), cancer, genetic disorders and others. By country, it is classified into the U. S., Canada, and Mexico. Major players operating in the market include, Astellas Pharma Inc., Mylan N. V., AbbVie Inc., Merck & Co., Inc. (Merck Sharp & Dohme Corp. ), Eli Lilly and Company, Pfizer Inc., Dynavax Technologies, Gilead Sciences, Inc., Bristol Myers Squibb, and Emergent BioSolutions (Cangene bioPharma).
KEY BENEFITS FOR STAKEHOLDERS
Key Market Segments
By Treatment Type
By Disease Type
By Country
List of key players profiled in the report:
LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request)
Furthermore, liver associated conditions also require liver transplant in many cases, where immunosuppressant drugs are used to prevent organ rejection. Thus, there are various types of liver treatments offered in the market such as anti-viral drugs, immunosuppressant drugs, vaccines, immunoglobulin, corticosteroid, targeted therapy, and chemotherapy drugs. In addition, these products are used to cure a range of liver diseases, which include hepatitis, autoimmune diseases, non-alcoholic fatty liver, and genetic disorders.
The major factors that contribute toward growth of the North America liver disease treatment market include increase in alcohol consumption & use of illegal drugs and The rise in prevalence of liver disease. Furthermore, it is also a primary cause for worsening of various liver conditions, which require treatment. For instance, consumption of large quantity of alcohol can lead to liver condition called alcoholic hepatitis, which, in turn, leads to liver inflammation that requires treatment. Furthermore, factors such as surge in geriatric population and increase in government and non-government awareness programs also boost growth of the North America liver disease treatment market. For instance, older patients who acquire hepatitis C infection are more likely to develop cirrhosis in the coming years, owing to accelerated fibrosis rate and decreased immunity.
However, stringent approval process related to drugs and resistance to antiviral drugs used in treatment of hepatitis B and hepatitis C of drugs restrict growth of the North America liver disease treatment market. For instance, approval processes require a huge capital investment. Moreover, any new drug manufacturing company that tries to enter into the market is bound to abide by these regulations. Therefore, these procedures are time consuming, which extends the time for their approval and commercialization and restricts growth of the market. Conversely, presence of strong pipeline products offer a lucrative opportunity for the market growth.
The North America liver disease treatment market is segmented on the basis of treatment type, disease type, and country to provide a detailed assessment of the market. By treatment type, the market is divided into antiviral drugs, immunosuppressants, vaccines, immunoglobulins, corticosteroids, targeted therapy, and chemotherapy. By disease type, it is divided into hepatitis, autoimmune diseases, non-alcoholic fatty liver disease (NAFLD), cancer, genetic disorders and others. By country, it is classified into the U. S., Canada, and Mexico. Major players operating in the market include, Astellas Pharma Inc., Mylan N. V., AbbVie Inc., Merck & Co., Inc. (Merck Sharp & Dohme Corp. ), Eli Lilly and Company, Pfizer Inc., Dynavax Technologies, Gilead Sciences, Inc., Bristol Myers Squibb, and Emergent BioSolutions (Cangene bioPharma).
KEY BENEFITS FOR STAKEHOLDERS
- This report entails a detailed quantitative analysis along with the current global North America liver disease treatment market trends from 2019 to 2027 to identify the prevailing opportunities along with the strategic assessments.
- The market size and estimations are based on a comprehensive analysis of key developments in the industry.
- A qualitative analysis based on innovative products facilitates strategic business planning.
- The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market
Key Market Segments
By Treatment Type
- Antiviral Drugs
- Immunosuppressants
- Vaccines
- Immunoglobulins
- Corticosteroids
- Targeted Therapy
- Chemotherapy
By Disease Type
- Hepatits
- Autoimmune Diseases
- Ischemic Stroke
- Stenosis
- Others
By Country
- U. S.
- Canada
- Mexico
List of key players profiled in the report:
- Astellas Pharma Inc.
- Mylan
- AbbVie Inc.
- Merck & Co., Inc. (Merck Sharp & Dohme Corp. )
- Eli Lilly and Company
- Dynavax Technologies
- Pfizer Inc.
- Gilead Sciences, Inc.,
- Bristol Myers Squibb
- Emergent BioSolutions (Cangene bioPharma)
LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request)
- Sanofi
- F. Hoffmann-La Roche AG
- Novartis AG
Table of Contents
Chapter 1: Introduction
Chapter 2: Executive Summary
Chapter 3: Market Overview
Chapter 4: North America Liver Disease Treatment Market, by Treatment Type
Chapter 5: North America Liver Disease Treatment Market, by Disease Type
Chapter 6: North America Liver Disease Treatment Market, by Country
Chapter 7: Company Profiles
List of Tables
List of Figures
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
